Androgen Receptor Splice Variant 7 Detected by Immunohistochemical Is an Independent Poor Prognostic Marker in Men Receiving Adjuvant Androgen-Deprivation Therapy After Radical Prostatectomy

Abstract

Background: To evaluate the predictive value of AR-V7 expression detected by immunohistochemical (IHC) in the prognosis of prostate cancer patients receiving adjuvant hormonal therapy (AHT) following by radical prostatectomy (RP).Methods: We retrospectively collected data of 110 patients with prostate cancer receiving RP, followed by AHT, from Tongji hospital. IHC analysis of AR-V7 expression was performed in a retrospective cohort. Results: In total, 110 patients were enrolled, of whom 21 patients (19.1%) were AR-V7-positive and 89 patients (80.9%) were AR-V7-negative. No significant differences in baseline characteristics were found between the two groups. AR-V7-positive patients had shorter progression‑free survival (PFS) (HR: 4.26; 95% CI, 1.55 to 11.68; P=0.003), shorter (cancer-special survival) CSS (HR: 22.47; 95% CI, 2.912 to 173.4; P=0.003) and shorter overall survival (OS ) (HR: 6.61; 95% CI, 1.40 to 31.20; P=0.017) compared to AR-V7-negative patients. In multivariate analysis, AR-V7 is an independent risk factor for shorter PFS (HR, 3.76; 95% CI, 1.63 to 8.70; P=0.002), shorter CSS (HR: 9.17; 95% CI, 1.48 to 55.56; P=0.017) and shorter OS (HR: 4.81; 95% CI, 1.28 to 17.86; P=0.020).Conclusion: The presence of AR-V7 in prostate cancer tissue is independently associated with an unfavorable prognosis for PFS, OS and CSS in patients who received AHT.